Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 6, 2003, Pages 809-821

  O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Bacillus Calmette Guerin; Biologic response modifiers; Bladder cancer; Interferon; Transitional cell carcinoma

Indexed keywords

ALPHA INTERFERON; AMINOGLYCOSIDE; ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; BCG VACCINE; CEPHALOSPORIN; CLARITHROMYCIN; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSERINE; DOXORUBICIN; EPIRUBICIN; ETHAMBUTOL; GEMCITABINE; INTERLEUKIN 2; ISONIAZID; MITOMYCIN C; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PHARMARUBICIN; PREDNISONE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPASMOLYTIC AGENT; SULFANILAMIDE; THIOTEPA; UNINDEXED DRUG; VALRUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; BLADDER CANCER; BLADDER SPASM; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CYSTITIS; DEPRESSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EPIDIDYMITIS; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATURIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; KIDNEY ABSCESS; LOW DRUG DOSE; MAINTENANCE THERAPY; MALAISE; MONOTHERAPY; MYALGIA; NEUROLOGIC DISEASE; PROSTATITIS; REVIEW; SEPSIS; SIDE EFFECT; TRANSURETHRAL RESECTION; URINARY FREQUENCY; URINARY URGENCY;

EID: 0346328320     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.6.809     Document Type: Review

References (52)

1. Jemal A, Murry T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).
2. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr. Opin. Oncol. 15, 227-233 (2003).
3. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med. Care 33, 828-841 (1995).
4. Takahashi T, Habuchi T, Kakehi Y et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 58, 5835-5841 (1998).
5. Holmang S, Hedelin H, Anderstrom C et al. The relationship among multiple recurrences, progression and prognosis in patients with stage TA and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J. Urol. 153, 1823-1827 (1995).
6. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vincente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol. 164, 680-684 (2000).
7. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vincente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 163, 73-78 (2000).
8. Lorenzo-Romero JG, Salinas-Sanchez AS, Gimenez-Bachs JM et al. Prognostic implications of p53 gene mutations in bladder tumors. J. Urol. 169, 492-499 (2003).
9. Heney NM. Natural history of superficial bladder cancer: prognostic features and long-term disease. Urol. Clin. North Am. 19, 429-433 (1992).
10. Nilsson S, Ragnhammar P, Glimelius B, Nygren P. SBU Group. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol. 40, 371-390 (2001).
11. Silvester RJ, Van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964 (2002).
12. Lamm DL, Steg A, Boccon-Gibaud L et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2,602 patients and comparison of chemotherapy complications. Prog. Clin. Biol. Res. 310, 335 (1989).
13. Belldegrun AS, Franklin JR, O'Donnell MA et al. Superficial bladder cancer: the role of interferon-alpha. J. Urol. 159, 1793-1801 (1998).
14. Martinez-Pineiro JA, Solsona E, Flores N et al. Improving die safety of BCG immunotherapy by dose reduction. Eur. Urol. 27(1), 13-18 (1997).
15. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol. 170, 964-969 (2003).
16. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353, 1689-1694 (1999).
17. Nadler R. Luo Y, Zhao W et al. Augmentation of Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced antitumor activity by enhancing delayed type hypersensitivity (DTH). Clin. Exp. Immunol. 131, 206-216 (2003).
18. Brown DH, Wagner TT, Bahnson RR. Interferons and bladder cancer. Urol. Clin. North Am. 27, 171-178 (2000).
19. Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 61, 2261-2266 (2001).
20. Luo Y, Chen X, Downs T, DeWolf WC, O'Donnell MA. Interferon-alpha 2B enhances BCG-induced T-helper type one responses in patients undergoing intravesical immunotherapy. J. Immunol. 162, 2399-2405 (1999).
21. Downs TM, Szilvasi A, O'Donnell MA. Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. J. Urol. 158, 2311-2315 (1997).
22. Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch. Ital. Urol. Androl. 67, 257-260 (1995).
23. Stricker P, Pryor K, Nicolson T et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 48, 957-962 (1996).
24. Esuvaranathan K, Kamaraj R, Mohan RS et al. A Phase IIB trial of BCG combined with interferon alpha for bladder cancer. J. Urol. 163(Suppl. 675), 152 (2000).
25. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2B plus low dose BCG is effective in patients with superficial bladder cancer previously failing BCG alone. J. Urol. 166, 1300-1305 (2001).
26. O'Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter Phase II trial of combination BCG plus interferon-alfa-2B for superficial bladder cancer. J. Urol. 169(Suppl. 256) (2003).
27. Mohanty NK, Malhotra V, Nayak RL, Arora RP. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother. 14, 194-197 (2002).
28. Luciani LG, Neulander E, Murphy WM, Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 58, 376-379 (2001).
29. Lam JS, Benson MC, O'Donnell MA et al. Bacillus Calmette-Guerin plus interferon alpha 2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. J. Urol. 167(Suppl. 190) (2002).
30. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy. Can. J. Urol. 10, 1790-1795 (2003).
31. Kaasinen E, Rintala E, Pere AK et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J. Urol. 164, 47-52 (2000).
32. Bazarbashi S, Raja MA, El Sayed A et al. Prospective Phase II trial of alternating intravesical bacillus Calmette-Guerin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results. J. Surg. Oncol. 74, 181-184 (2000).
33. Torti FM, Shortliffe LD, Williams RD et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J. Clin. Oncol. 6, 476-483 (1988).
34. O'Donnell MA, Hartman K. National Phase II BCG/IFN-alpha Investigator Group. An evaluation of BCG plus interferon-alpha-2B toxicity in a national multicenter Phase II trial. J. Urol. 167(Suppl. 188) (2002).
35. Fisman D, Barlam T, Dorman S, Holland S, O'Donnell M. Risk factors for 'BCGosis' in bladder cancer patients: a case control study. Clin. Infect. Dis. (1999) (Abstract 29).
36. Denis M. Recombinant murine beta interferon enhances resistance of mice to systemic Mycobacterium avium infection. Infect. Immun. 59, 1857-1859 (1991).
37. Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. J. Urol. 161, 1568-1569 (1999).
38. Downs TM, Chen X, De Wolf W, O'Donnell MA. Urinary cytokine expression following intravesical BCG treatment and its correlation with patient symptoms. Proc. N. Engl. Section Am. Urol. Assoc. (1997).
39. Durek C, Rusch-Gerdes S, Joacham D, Bohle A. Sensitivity of BCG to modern antibiotics. Eur. Urol. 37(Suppl. 1), 21-25 (2000).
40. Koukol SC, DeHaven JI, Riggs DR, Lamm DL. Drug therapy of bacillus Calmette-Guerin sepsis. Urol. Res. 22, 373-376 (1995).
41. Bohle A, Rusch-Gerdes S, Ulmer AJ, Braasch H, Jocham D. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. J. Urol. 155, 1892-1896 (1996).
42. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guerin for carcinoma in situ of the bladder. Br. J. Urol. 75, 180-184 (1995).
43. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol. 141, 22-29 (1989).
44. Bui TT, Schellhammer PF. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49, 687-690 (1997).
45. Steinberg G, Bahnson R, Brosman S et al. Efficacy and safety of Valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J. Urol. 163, 761-767 (2000).
46. Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol. 20, 3193-3198 (2002).
47. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 158, 62-67 (1997).
48. Burns JA, Williams RD, Hedican SP, O'Donnell MA. The treatment of upper tract transitional cell carcinoma (TCCa) with BCG and interferon-alpha (IFN). Proc. North Cent. Section Am. Urol. Assoc. (2001).
49. Luo Y Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in bacillus Calmette-Guerin (BCG)-induced IFN-α production: cytokine promotion and simulation of BCG effect. Cytokine 21, 17-26 (2003).
50. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guérin (BCG). J. Immunol. 163, 4246-4252 (1999).
51. Izawa JI, Sweeney P, Perrotte P et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various anti-angiogenic effects including endothelial cell apoptosis. Clin. Cancer Res. 8, 1258-12570 (2002).
52. Luo Y, Chen X, Han R, O'Donnell MA. Recombinant bacillus Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin. Exp. Immunol. 123, 264-270 (2001).